Feb 2010
Signum Biosciences is proud to announce the appointment of Dr. Diane Thiboutot to its scientific advisory board. Dr. Thiboutot is a research leader in the regulation of sebum production, acne and is a research collaborator for testing STM activity. Read More See Dr. Thiboutot's Bio
Jan 2010
Signum Biosciences has been awarded a $270K grant from the Alzheimer's Drug Discovery Foundation (ADDF) to investigate, "PP2A: A novel therapeutic target for Alzheimer's Disease". Read More
July 2009
Dr. Jeffrey Stock et al. presents a poster at the International Conference on Alzheimer's Disease (Vienna) highlighting "PP2A as a novel pharmaceutical target for the treatment of Alzheimer's Disease" and the effects of STMs on PP2A methylation levels and phosphatase activity. Click here to see the poster
Interested in a job at Signum? Visit our job postings section for a listing of our open positions.
In collaboration with the University of Pennsylvania we are investigating the effects of GPMs on UVB-induced inflammation.
Signum Biosciences, in collaboration with Rohto Pharmaceutical, is proud to announce the launch of Arazine™, one of Signum’s anti-inflammatory compounds, in Japan. 
In collaboration with the University of Medicine and Dentistry of New Jersey, we are investigating the effects of PPM compounds on α-synuclein phosphorylation in mouse models of Parkinson’s Disease.